http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110804084-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate | 2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110804084-B |
| titleOfInvention | Quaternary phosphonium salt diosgenin derivative and synthesis method and application thereof |
| abstract | The invention belongs to the technical field of medicine and pharmacology, and discloses diosgenin quaternary phosphorus salt derivatives, a preparation method and application thereof. Pharmacological experiments show that: all the synthesized diosgenin quaternary phosphonium salt derivatives have obvious inhibition effects on A549 cells, H1975 cells, HCT-116 cells and Aspc-1 cells, the antitumor activity of the derivatives is superior to that of diosgenin, the antitumor activity of most of the derivatives on Ramos cells and A431 cells is superior to that of diosgenin, and part of the derivatives have low toxicity on HBE cells and LO-2 cells. |
| priorityDate | 2019-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.